Details

Autor(en) / Beteiligte

• Kleiter, Ingo
• Hellwig, Kerstin
• Berthele, Achim
• Kümpfel, Tania
• Linker, Ralf A
• Hartung, Hans-Peter
• Paul, Friedemann
• Aktas, Orhan

Titel

Failure of natalizumab to prevent relapses in neuromyelitis optica

Ist Teil von

• Archives of neurology (Chicago), 2012-02, Vol.69 (2), p.239

Ort / Verlag

United States

Erscheinungsjahr

2012

Quelle

MEDLINE

Beschreibungen/Notizen

• To describe first experiences with the integrin inhibitor natalizumab, given to patients with suspected relapsing-remitting multiple sclerosis (MS) who were later diagnosed with aquaporin 4-positive neuromyelitis optica (NMO). Retrospective case series. Neurology departments at tertiary referral centers in Germany. Patients with NMO who tested positive for antibodies to aquaporin 4. Treatment with natalizumab. Relapses and accumulation of disability. We identified 5 patients (4 female; median age, 45 years) who were initially diagnosed with MS and treated with natalizumab before diagnosis of NMO was established. Natalizumab was given as escalation therapy after failure of first- or second-line immunomodulatory therapies for MS. During natalizumab therapy (median duration, 8 infusions; range, 2-11 infusions), all 5 patients displayed persisting disease activity; a total of 9 relapses occurred (median duration to relapse, 120 days; range, 45-230 days) after the start of treatment. Four patients had an accumulation of disability and 1 patient died 2 months after cessation of natalizumab treatment. Our results suggest that natalizumab fails to control disease activity in patients with NMO. Neuromyelitis optica should be considered as a differential diagnosis in patients with suspected MS who are unresponsive to natalizumab therapy.